Soligenix (NASDAQ:SNGX) Posts Earnings Results, Beats Expectations By $0.04 EPS

Soligenix (NASDAQ:SNGX) posted its earnings results on Friday. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04, Zacks reports.

Soligenix Stock Performance

SNGX stock traded up $0.01 during trading on Friday, hitting $0.39. 130,758 shares of the company’s stock traded hands, compared to its average volume of 304,500. Soligenix has a 52 week low of $0.28 and a 52 week high of $6.23. The stock has a market capitalization of $5.81 million, a price-to-earnings ratio of -0.23 and a beta of 1.93. The business has a fifty day simple moving average of $0.41 and a 200 day simple moving average of $0.81.

Institutional Trading of Soligenix

Hedge funds have recently made changes to their positions in the business. Armistice Capital LLC bought a new position in shares of Soligenix in the 3rd quarter valued at about $821,000. Two Sigma Investments LP bought a new stake in Soligenix during the third quarter worth approximately $102,000. Geode Capital Management LLC raised its position in Soligenix by 88.8% during the fourth quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 37,811 shares during the period. Virtu Financial LLC purchased a new stake in Soligenix during the third quarter valued at approximately $59,000. Finally, Banco BTG Pactual S.A. bought a new stake in shares of Soligenix in the 3rd quarter valued at approximately $54,000. 3.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.